PROTAC BRD4 ligand-2 is primarily used in the field of targeted protein degradation. It is designed to specifically target the BRD4 protein, which plays a critical role in regulating gene expression and is often implicated in various cancers. By utilizing the PROTAC (Proteolysis Targeting Chimera) technology, this ligand facilitates the degradation of BRD4, thereby inhibiting its function and potentially halting cancer progression. This approach offers a promising strategy for developing novel cancer therapies, particularly for diseases where BRD4 overexpression or dysregulation is a key driver. Additionally, it serves as a valuable tool in biomedical research for studying the role of BRD4 in cellular processes and disease mechanisms.